Posted by Michael Wonder on 26 Mar 2024
FDA approves Merck’s Winrevair (sotatercept-csrk), a first in class treatment for adults with pulmonary arterial hypertension (WHO Group 1)
26 March 2024 - Winrevair on top of background therapy significantly improved exercise capacity and multiple important secondary outcome measures compared to background therapy alone.
Merck announced today that the US FDA has approved sotatercept-csrk (Winrevair 45 mg & 60 mg for injection) for the treatment of adults with pulmonary arterial hypertension (World Health Organization Group 1) to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events.
